Sign In
Buy INCY
$119.80
-0.800 (-0.663%)
At Close: Aug 05, 2026
Here are Wall Street's favorite stocks in the sector expected to grow profits the most in 2024
09:13am, Tuesday, 09'th Jan 2024
Each earnings reporting season, you can count on a flurry of articles with headlines saying companies “beat” consensus estimates for quarterly profits. But that “success” alone means nothing.
5 Biotech Acquisition Targets To Accumulate In 2024
01:05pm, Thursday, 21'st Dec 2023
Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provid
The 3 Most Undervalued Biotech Stocks to Buy in December
02:30pm, Friday, 15'th Dec 2023
As technology advances in our era, biotechnology is not far behind. Modern day medical advancements are impressive, and the company's making these strides have incredible results to show for it.
Incyte Stock Is the S&P 500's Top Performer. Here's Why It's Surging.
12:43pm, Tuesday, 12'th Dec 2023
Shares of the biopharmaceutical company are on pace for their best day in more than six years.
3 Biotech Stocks That Are Poised to Have Breakthroughs in 2024
08:18am, Sunday, 12'th Nov 2023
When it comes to biotech stocks, I usually like to take a “Goldilocks” approach. This involves investing in biotech companies that have one or more promising drugs in mid-to-late stage clinical tr
7 Underappreciated Biotech Stocks to Pick Up on the Cheap
10:01pm, Thursday, 09'th Nov 2023
Amid some rising questions for the economy, value-seeking investors may want to consider underappreciated biotech stocks. As a sector that, while not immune to broader pressures, generally manages to
Incyte (INCY) Beats on Q3 Earnings, Misses Revenue Estimates
01:31pm, Tuesday, 31'st Oct 2023
Incyte's (INCY) third-quarter 2023 earnings beat estimates, while revenues miss the same. The company tightens Jakafi net product revenue guidance for 2023.
Incyte Corporation (INCY) Q3 2023 Earnings Call Transcript
12:23pm, Tuesday, 31'st Oct 2023
Incyte Corporation (NASDAQ:INCY ) Q3 2023 Earnings Call Transcript October 31, 2023 8:00 AM ET Company Participants Ben Strain - Head of Investor Relations Herve Hoppenot - President and Chief Executi
Drugmaker Incyte's quarterly profit beats on lower costs
09:48am, Tuesday, 31'st Oct 2023
Incyte reported a third-quarter profit on Tuesday that beat analysts' estimates as lower costs helped offset weak sales of its blood cancer drug Jakafi.
Incyte (INCY) Surpasses Q3 Earnings Estimates
09:46am, Tuesday, 31'st Oct 2023
Incyte (INCY) came out with quarterly earnings of $1.10 per share, beating the Zacks Consensus Estimate of $1.09 per share. This compares to earnings of $0.60 per share a year ago.
Incyte (INCY) Stock Plummets 29.6% Year to Date: Here's Why
02:16pm, Friday, 13'th Oct 2023
Incyte (INCY) loses 29.6% year-to-date as competition increases for Jakafi and the company suffers pipeline setbacks.
Incyte (INCY) Posts Upbeat Data From Phase II Vitiligo Study
12:47pm, Thursday, 12'th Oct 2023
Incyte (INCY) announces new positive 52-week data from its mid-stage study of povorcitinib for the treatment of adult patients with extensive nonsegmental vitiligo.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress.
3 Biotech Stocks That Should Be on Every Investor's Radar This Fall
02:15pm, Wednesday, 20'th Sep 2023
The Federal Reserve's decision on interest rates will impact the short-term outlook of the economy. However, even with higher-for-longer interest rates, drug discovery moves on.
Incyte (INCY) Down on FDA Nod for Another Myelofibrosis Drug
09:46am, Tuesday, 19'th Sep 2023
Incyte (INCY) declines on potential competition for lead drug Jakafi from Ojjaara for the treatment of intermediate or high-risk myelofibrosis.
